PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
56.85%
Some net income increase while TRVN is negative at -0.98%. John Neff would see a short-term edge over the struggling competitor.
-0.49%
Negative yoy D&A while TRVN is 6.74%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-97.78%
Both cut yoy SBC, with TRVN at -5.44%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
251.75%
Well above TRVN's 104.16% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
214.04%
AP growth well above TRVN's 100.00%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-132.83%
Both reduce yoy usage, with TRVN at -125.73%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
No Data
No Data available this quarter, please select a different quarter.
28.81%
Operating cash flow growth at 75-90% of TRVN's 37.31%. Bill Ackman would recommend further refinements to match competitor’s CFO gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.00%
Both yoy lines negative, with TRVN at -150.00%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.